Cellectis S.A.

CLLS

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001627281

SEC filings (opens in a new tab)

No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Cellectis S.A. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022 All holders in Q3 2022

13F holders of CLLS: Q3 2022 compared with Q4 2022
Measure	Q3 2022	Q4 2022	Change
Holders	50	40	−10
Shares	10.3M	8.73M	−1.57M (−15.2%)
Value	$23.6M	$18.3M	−$5.27M (−22.3%)

New holders (6)

Institutions that held Cellectis S.A. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to CLLS in Q4 2022
Institution	Shares	Value	% of portfolio
Susquehanna International Group, LLP	58,087	$122.0K	0.00%
Ergoteles LLC	19,365	$40.7K	0.00%
Goldman Sachs Group Inc	18,208	$38.2K	0.00%
Old Mission Capital LLC	11,752	$24.7K	0.00%
Money Concepts Capital Corp	515	$1.08K	0.00%
BNP Paribas Arbitrage, SA	166	$349	0.00%

Sold out (16)

Institutions that held Cellectis S.A. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of CLLS in Q4 2022
Institution	Shares, Q3 2022	Value, Q3 2022
State Street Corp	262,368	$601.0K
Mirae Asset Global Investments Co., Ltd.	210,659	$482.0K
Woodline Partners LP	169,802	$389.0K
Marshall Wace, LLP	108,744	$249.0K
Kettle Hill Capital Management, LLC	104,596	$240.0K
Vanguard Group Inc	85,864	$197.0K
Hudson Bay Capital Management LP	74,532	$171.0K
WS Management LLLP	50,907	$117.0K
Baird Financial Group, Inc.	32,640	$74.0K
Balyasny Asset Management LLC	18,352	$42.0K
Two Sigma Advisers, LP	14,900	$34.0K
Two Sigma Investments, LP	13,303	$30.0K
SEI Investments Co	10,977	$25.0K
Princeton Capital Management LLC	10,594	$24.0K
Daiwa Securities Group Inc.	40	$0
China Universal Asset Management Co., Ltd.	168	$0